NTLA stock forecast
Our latest prediction for Intellia Therapeutics, Inc.'s stock price was made on the May 14, 2018 when the stock price was at 24.59$.
In the short term (2weeks), NTLA's stock price should underperform the market by -0.67%. During that period the price should oscillate between -8.77% and +9.60%.
In the medium term (3months), NTLA's stock price should underperform the market by -1.66%. During that period the price should oscillate between -20.42% and +25.53%.Get email alerts
Create a solid portfolio with NTLA
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
At the moment the company generates 30M USD in revenues.
On its last earning announcement, the company reported a loss of -1.98$ per share.
The book value per share is 6.47$
Three months stock forecastMay 14, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|